191 related articles for article (PubMed ID: 37200263)
21. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Enomoto T; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Surg Oncol; 2018 Sep; 25(9):2756-2766. PubMed ID: 29971677
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
24. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
[TBL] [Abstract][Full Text] [Related]
25. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
Cicin İ; Özatlı T; Türkmen E; Özturk T; Özçelik M; Çabuk D; Gökdurnalı A; Balvan Ö; Yıldız Y; Şeker M; Özdemir N; Yapar B; Tanrıverdi Ö; Günaydin Y; Menekşe S; Öksüzoğlu B; Aksoy A; Erdogan B; Bekir Hacıoglu M; Arpaci E; Sevinç A
Balkan Med J; 2016 Sep; 33(5):517-524. PubMed ID: 27761279
[TBL] [Abstract][Full Text] [Related]
26. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
28. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
[TBL] [Abstract][Full Text] [Related]
30. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract][Full Text] [Related]
31. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Surg Oncol; 2018 Sep; 27(3):433-440. PubMed ID: 30217299
[TBL] [Abstract][Full Text] [Related]
32. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
34. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
35. L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas.
Mancusi de Carvalho JP; Salim RC; Carvalho FM; Nogueira Dias Genta ML; Baracat EC; Carvalho JP
J Clin Pathol; 2020 Nov; 73(11):748-753. PubMed ID: 32366597
[TBL] [Abstract][Full Text] [Related]
36. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
37. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
[TBL] [Abstract][Full Text] [Related]
38. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.
Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():51-55. PubMed ID: 31739121
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma.
Lee YK; Park NH; Lee H
Int J Gynecol Cancer; 2012 Mar; 22(3):434-41. PubMed ID: 22266933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
